In patients with metastatic NSCLC, pembrolizumab is approved in conjunction with the PD-L1 IHC 22C3 pharmDx assay (Dako), a companion diagnostic test that identifies suitable patients for pembrolizumab therapy [216]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.